These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23743535)

  • 1. Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial).
    Menon G; Chandran M; Sivaprasad S; Chavan R; Narendran N; Yang Y
    Eye (Lond); 2013 Aug; 27(8):959-63. PubMed ID: 23743535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.
    Tufail A; Patel PJ; Egan C; Hykin P; da Cruz L; Gregor Z; Dowler J; Majid MA; Bailey C; Mohamed Q; Johnston R; Bunce C; Xing W;
    BMJ; 2010 Jun; 340():c2459. PubMed ID: 20538634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Arias L; Caminal JM; Casas L; Masuet C; Badia MB; Rubio M; Pujol O; Arruga J
    Br J Ophthalmol; 2008 Dec; 92(12):1636-41. PubMed ID: 18782803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
    Gupta B; Adewoyin T; Patel SK; Sivaprasad S
    Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction with intravitreal bevacizumab every two weeks in the management of neovascular age-related macular degeneration.
    Barikian A; Mahfoud Z; Abdulaal M; Safar A; Bashshur ZF
    Am J Ophthalmol; 2015 Jan; 159(1):131-7. PubMed ID: 25308787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of intravitreal administration of bevacizumab on macular edema and visual acuity in age-related macular degeneration with subfoveolar choroidal neovascularisation.
    Ristić D; Vukosavljević M; Draganić B; Cerović V; Petrović N; Janićijević-Petrović M
    Vojnosanit Pregl; 2013 Jul; 70(7):660-3. PubMed ID: 23984614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.
    Mekjavic PJ; Kraut A; Urbancic M; Lenassi E; Hawlina M
    Acta Ophthalmol; 2011 Nov; 89(7):647-53. PubMed ID: 19860774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for neovascular age-related macular degeneration in China.
    Li X; Hu Y; Sun X; Zhang J; Zhang M;
    Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.
    Moja L; Lucenteforte E; Kwag KH; Bertele V; Campomori A; Chakravarthy U; D'Amico R; Dickersin K; Kodjikian L; Lindsley K; Loke Y; Maguire M; Martin DF; Mugelli A; Mühlbauer B; Püntmann I; Reeves B; Rogers C; Schmucker C; Subramanian ML; Virgili G
    Cochrane Database Syst Rev; 2014 Sep; 9(9):CD011230. PubMed ID: 25220133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
    Retina; 2006; 26(5):495-511. PubMed ID: 16770255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of good visual outcomes in patients with neovascular age-related macular degeneration in daily practice.
    Prieto-Del-Cura M; Villafruela-Güemes I; Recio-Gamo E; Sastre-Ibañez M; Fuentes-Ferrer ME
    J Fr Ophtalmol; 2020 Dec; 43(10):989-995. PubMed ID: 33081995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular age-related macular degeneration in an Australian population.
    Luu ST; Gray T; Warrier SK; Patel I; Muecke JS; Casson R; Gilhotra JS
    Clin Exp Ophthalmol; 2010 Oct; 38(7):659-63. PubMed ID: 20456433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration.
    Aisenbrey S; Ziemssen F; Völker M; Gelisken F; Szurman P; Jaissle G; Grisanti S; Bartz-Schmidt KU
    Graefes Arch Clin Exp Ophthalmol; 2007 Jul; 245(7):941-8. PubMed ID: 17186262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.